Making the Cardiorenal Connection with SGLT2 inhibitors
Published: 25 February 2021
This educational symposium was part of the eSPACE CRM meeting held on 22-24 January 2021.
The session focuses on latest data and practical implication of SGLT2 Inhibitors in Heart Failure patients.
This educational symposium will allow the audience to:
- Understand the pathophysiological connections between cardiovascular disease and kidney disease
- Understand how SGLT2 inhibition modifies cardiovascular and kidney function to affect patient outcomes
- Identify individuals at risk of incident and progressive cardiorenal disease and utilise SGLT2 inhibitors appropriately for prevention and treatment of the associated conditions
- Explain how recent guideline updates position SGLT2 inhibitors within the treatment regimen for patients with, or at risk of, cardiorenal disease
Time - Session title and objective - Speaker(s)
- 10 mins - Welcome and Introductions - Carol Pollock
- 20 mins - The Cardiac Connection - Mark Petrie
- 20 mins - The Renal Connection - David Cherney
- 10 mins - Joined-up thinking: Evolving guidelines for cardiorenal disease management - All faculty
More from this programme
Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory.
During his PhD training, Dr. Cherney was the recipient of a Kidney Foundation of Canada Scholarship and then a three-year KRESCENT Fellowship. He is currently supported by a five-year Canadian Diabetes Association-KRESCENT Program Joint New Investigator Award and receives operating funding from the Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation and Kidney Foundation of Canada.